Updates are available Correction dated 2025-08-19
Click to view Correction: https://doi.org/10.1007/s12185-025-04054-5
-
Authors
Yamaguchi, Hiroki https://orcid.org/0000-0002-0571-7495
Iino, Masaki https://orcid.org/0000-0002-3471-0890
Kowata, Shugo
Yamamoto, Ryusuke
Yamanouchi, Jun
Imamura, Yutaka
Kirito, Keita
Yokoyama, Kenji https://orcid.org/0000-0003-2452-7248
Ito, Tomoki https://orcid.org/0000-0001-5419-9156
Ishikawa, Tatsunori
Shiratsuchi, Motoaki https://orcid.org/0000-0002-0403-0122
Tomiyama, Yoshiaki https://orcid.org/0000-0001-7645-0989
Kamiya, Harumi
Zhang, Jessica
Jamieson, Brian D.
-
Funding
Funding for this research was provided by:
Sobi
- License Information
-
More Information
Article History
Received: 6 January 2025
Revised: 1 May 2025
Accepted: 1 May 2025
First Online: 20 May 2025
Change Date: 17 August 2025
Change Type: Update
Change Details: The original online version of this article was revised for retrospective open access.
Change Date: 19 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12185-025-04054-5
Declarations
:
: Hiroki Yamaguchi has received consulting fees from AbbVie GK., Alexion Pharma G.K., Daiichi Sankyo Co Ltd., MSD K.K., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K. and PharmaEssentia CO., Ltd.; has received honoraria from AbbVie GK., Alexion Pharma G.K., Asahi Kasei Pharma K. K., AstraZeneca K.K., Astellas Pharma Inc., Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co Ltd., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., PharmaEssentia Co., Ltd., Shionogi & Co., Ltd. and Zeria Pharmaceutical Co., Ltd.; and is on the editorial board of the International Journal of Hematology. Masaki Iino, Shugo Kowata, Ryusuke Yamamoto, Jun Yamanouchi, Yutaka Imamura, Tatsunori Ishikawa and Motoaki Shiratsuchi declare that they have no conflict of interest. Keita Kirito has received honoraria from GlaxosmithKline K.K., Pharmaessentia Co., Ltd. and Takeda. Kenji Yokoyama has received consulting fees from Kowa Co., Ltd; and has received honoraria from AbbVie G.K., Argenx, Asahi Kasei Pharma K. K., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Genmab K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd. and PharmaEssentia Co., Ltd. Tomoki Ito has received honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Novartis, Sanofi and Takeda. Yoshiaki Tomiyama has received consulting fees from Argenx, Kissei, Kyowa Kirin, MBL, Megakaryon, Novartis, Sobi, Sysmex and Takeda; and has received honoraria from Kissei, Kyowa Kirin, Novartis and Sysmex. Harumi Kamiyama, Jessica Zhang and Brian D Jamieson are employees of Sobi.
